Epidemiology and Management of invasive infections among people who Use drugs (EMU)

Monash University0 个研究点目标入组 146 人开始时间: 2022年8月30日最近更新: 2023年2月6日

适应症

试验速览

暂无简介。

•Subjects will be eligible for this study if they:
•*Are adult patients aged at least 18 years
•*Have a history of current intravenous drug use (IDU). Current IDU defined as use within six months prior to admission.
•*Are admitted to hospital for management of invasive bacterial or fungal infection (proven or presumed).
•Invasive infections are defined by treating physician diagnosis (proven or presumed) of the following infections:
•*Infective endocarditis
•*Epidural abscess
•*Bone and join infection (including osteomyelitis, septic arthritis, or prosthetic joint infection)
•*Other deep abscess (excluding acute bacterial skin and skin structure infections (ABSSSI) but including soft tissue such as muscle/ lung/ liver/ spleen/ cerebral with no evidence of infective endocarditis)
•*Bacteraemia or candidaemia not otherwise specified (excluding infective endocarditis)

•EMU-Audit:
•*Patients with acute bacterial skin and skin structure infections (ABSSSI) only and no evidence of invasive infection
•*Patients admitted for management of viral infection only (HAV/ HBV/ HCV/ HIV) and no evidence of bacterial or fungal infection
•*Patients admitted for management of viral or bacterial meningitis only with no evidence of above invasive infections
•*Patients admitted for a reason unrelated to an acute infection (such as trauma), who subsequently develop an invasive infection
•EMU-Cohort:
•As per exclusion criteria for EMU-Audit patients AND
•*Refusal to participate
•*Patient unable to give informed consent including if not fluent in English to be able to understand the PICF and participate in the consent process
•*No access to landline or mobile telephone for follow up

发起方